Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Fluidigm

Fluidigm
1999 FOUNDED
PUBLIC STATUS
501-600 EMPLOYEES
FLDM STOCK SYMBOL
2 INVESTMENTS
$13.59 SHARE PRICE (As of Friday Closing)
Description

Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. It sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm's revenue comes from the sale of Consumables. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of revenue is generated in the United States followed by EMEA and Asia-Pacific.

Formerly Known As
Mycometrix
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Commercial Products
Other Industries
Other Semiconductors
Biotechnology
Stock Exchange
NAS
Primary Office
  • 7000 Shoreline Court
  • Suite 100
  • San Francisco, CA 94080
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Fluidigm’s full profile, request a free trial.

Fluidigm Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$4.65 - $14.90 $986M $14.29 -$1.49 944K 69M

Fluidigm Financials Summary

In Thousands,
USD
TTM
31-Dec-2018
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 553,268 553,268 360,427 335,614
Revenue 112,964 112,964 101,937 104,446
EBITDA (30,955) (30,955) (39,366) (56,419)
Net Income (59,013) (59,013) (60,535) (75,985)
Total Assets 303,647 303,647 287,351 306,395
Total Debt 172,058 172,058 195,238 194,951
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Fluidigm Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Fluidigm‘s full profile, request access.

Request full access to PitchBook

Fluidigm Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Fluidigm‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Fluidigm Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 00000000 13-Feb-2014 000000000000000000 00000 Medical Supplies
Helicos Biosciences (Patent portfolio) 28-Jun-2013 Corporate Asset Purchase 00.00 Buildings and Property
To view this company’s complete investment and acquisition history, request access »

Fluidigm Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Fluidigm‘s full profile, request access.

Request full access to PitchBook

Fluidigm Executive Team (8)

Name Title Board
Seat
Contact
Info
Christopher Linthwaite Chief Executive Officer, President, Director & Chief Operating Officer
Vikram Jog Chief Financial Officer & Principal Accounting Officer
Fredric Walder Chief Operating Officer
Steven McPhail Chief Commercial Officer
Peter Karlberg Ph.D Senior Director - Applied Markets EMEA

1 Former Executive

You’re viewing 5 of 8 executives. Get the full list »

Fluidigm Board Members (8)

Name Representing Role Since Contact
Info
Nicolas Barthelemy Self Board Member 000 0000
Samuel Colella Self Chairman & Director 000 0000

6 Former Board Members

You’re viewing 2 of 8 board members. Get the full list »